Navigation Links
BZL101 in Medical News

Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Announces Presentation at the National Cancer Institute

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces Cost Control Measures Taken

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces 2007 Financial Results and Highlights

...er Research (AACR). The presentation described how bzl101 elicits its cytotoxic activity on cancer cel... patients into a Phase 1/2 clinical trial of bzl101 for the treatment of advanced breast cancer, after presenting positive Phase 1 findings of bzl101 at the American Association of Cancer Resear...
BZL101 in Medical Technology

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth Internationa...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...

Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles

- Results Presented at American Society of Clinical Oncology 44TH Annual Meeting - EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in...

Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101

BZL101 selectively kills cancer cells but not normal cells EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms un...

Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial

...es of its innovative breast cancer drug candidate, bzl101 were well tolerated. As a result, the company will... available efficacy information." About BZL101 bzl101 is an oral drug designed for the treatment of adva...argely on glycolysis (>85%) for energy production. bzl101 leads to energy collapse in cancer cells by inhibi...

Bionovo to Present Recent Findings of BZL101, Its Anti-cancer Agent, at the American Association of Cancer Research

... for cancer cell apoptosis (cell death) induced by bzl101 while leaving normal cells unaffected. As explaine...ctor of Cancer Research at Bionovo, the ability of bzl101 to induce apoptosis is due to attenuation of mitoc... of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced brea...

Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial

...men's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancrea...
BZL101 in Biological Technology

Bionovo Announces 2008 Highlights and Year-End Financial Results

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Reports Third Quarter 2008 Financial Results

... of advanced breast cancer, menopausal hot flashes, and menopausal vaginal atrophy. Recent advances have included: -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer has now been completed successfully, showing positive safety and tolerabil...

Bionovo Reports Second Quarter 2008 Financial Results

...rence of $4.6 million. Company Highlights -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer continues su...al trials for both MF101 and VG101." "We are very excited at the progress bzl101 is making in the clinical trials for advanced breast cancer. This drug cand...

Bionovo Reports First Quarter 2008 Financial Results

...th $33.3 million, a difference of $3.9 million. Company Highlights -- Patient enrollment and dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. Presentations, papers and scientific discussions have expounded the mechanis...

Bionovo Announces Third Quarter 2007 Financial Results

...dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. -- Bionovo presented data on bzl101 at the AACR-NCI-EORTC International Conference...r Targets and Cancer Therapeutics showing that bzl101 selectively elicits its cytotoxic activity on canc...
Other Tags
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into the NAPW VIP Professional Woman of ... distinction for leadership in academics. With more than 700,000 ... the nation’s leading networking organization exclusively for professional women. ... distinction,” said NAPW President Star Jones. “She is a ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Selma Tansey as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Selma with this important honor," said ...
(Date:6/1/2015)... June 01, 2015 Ticket Down announces that ... NBA Western Conference Finals and now will face the Cleveland ... be held at the Oracle Arena in Oakland and the ... 2014-15 National Basketball Association season, the Golden State Warriors were ... a team that learned from their playoff failures from the ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 The Delta ... health programs and organizations in Michigan, Ohio and Indiana ... deadline of Sept. 30, 2015 has been set. , ... in grants to organizations that specifically focus on children’s ... primarily address oral health in adults. Each grant request ...
(Date:6/1/2015)... The Muscular Dystrophy Association is offering an ... the sold out 2015 Bank of America Chicago ... by signing up through the organization's nationwide endurance ... , This national endurance program includes world-class training ... a supportive community of teammates, volunteers, coaches and ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
Other Contents